SCHEMBL1100544

SCHEMBL1100544

O=C1NC(=O)C(CNS(=O)(=O)c2cccc(Oc3ccccc3C(F)(F)F)c2)N1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BRAF P15056 5/20 0.38
FDFT1 P37268 1/20 0.38
POLB P06746 1/20 0.35
MAPT P10636 1/20 0.35
KDM4C Q9H3R0 1/20 0.35
SLC22A12 Q96S37 2/20 0.35
NR3C1 P04150 1/20 0.34
PGR P06401 1/20 0.34
AR P10275 1/20 0.34
ESR2 Q92731 1/20 0.34
TSHR P16473 1/20 0.34
MEN1 O00255 1/20 0.34
CNR1 P21554 1/20 0.34
GPR183 P32249 1/20 0.34
CNR2 P34972 1/20 0.34
KMT2A Q03164 1/20 0.34
HTR1A P08908 1/20 0.34
HTR7 P34969 1/20 0.34
NR1H2 P55055 1/20 0.33
NR1H3 Q13133 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1108463 1.00 BRAF (0.38) BRAFFDFT1POLBMAPTKDM4C
SCHEMBL1100926 0.84 PGR (0.44) BRAFFDFT1MAPTNR3C1PGR
SCHEMBL1108519 0.84 PGR (0.44) BRAFFDFT1MAPTNR3C1PGR
SCHEMBL1100111 0.80 PGR (0.42) POLBMAPTPGRMEN1KMT2A
SCHEMBL1108510 0.80 PGR (0.42) POLBMAPTPGRMEN1KMT2A
SCHEMBL1099759 0.79 PGR (0.49) MAPTPGRMEN1KMT2AL3MBTL1
SCHEMBL1100507 0.79 HTT (0.43) POLBMAPTPGRMEN1KMT2A
SCHEMBL1108543 0.79 HTT (0.43) POLBMAPTPGRMEN1KMT2A
SCHEMBL1099734 0.78 LGALS8 (0.42) FDFT1POLBMAPTPGRMEN1
SCHEMBL1108479 0.78 LGALS8 (0.42) FDFT1POLBMAPTPGRMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-1962641-B Metalloproteinase inhibitors ASTRAZENECA AB 2012-07-04 CN disclosed
US-8153673-B2 Metalloproteinase inhibitors ASTRAZENECA AB (SE) 2012-04-10 US disclosed
US-20100273849-A1 Metalloproteinase Inhibitors ASTRAZENECA AB (SE) 2010-10-28 US disclosed
EP-1370537-B1 METALLOPROTEINASE INHIBITORS ASTRAZENECA AB (SE) 2010-10-13 EP disclosed
US-7666892-B2 Metalloproteinase inhibitors ASTRAZENECA AB (SE) 2010-02-23 US disclosed
US-20080262045-A1 Metalloproteinase Inhibitors ASTRAZENECA AB (SE) 2008-10-23 US disclosed
US-7368465-B2 Respiratory system disorders; antiarthritic agents; anticancer agents; bone disorders ASTRAZENECA AB (SE) 2008-05-06 US disclosed
US-20040138276-A1 Metalloproteinase inhibitors ASTRAZENECA AB (SE) 2004-07-15 US disclosed
EP-1370537-A1 METALLOPROTEINASE INHIBITORS AstraZeneca AB (SE) 2003-12-17 EP disclosed
WO-2002074751-A1 METALLOPROTEINASE INHIBITORS ASTRAZENECA AB (SE) 2002-09-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100273849-A1 Metalloproteinase Inhibitors MMP9, MMP12, MMP11 BRAF 3532/4885FDFT1 2712/4885POLB 1244/4885
US-20080262045-A1 Metalloproteinase Inhibitors MMP9, MMP12, MMP11 BRAF 3532/4885FDFT1 2712/4885POLB 1244/4885
US-20040138276-A1 Metalloproteinase inhibitors MMP9, MMP11, MMP7 BRAF 4193/4885FDFT1 4129/4885POLB 1317/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.